CSF1R and hepatocellular carcinoma: For example, the highly specific CSF-1R tyrosine kinase inhibitor, PLX3397, has been shown to repolarise TAMs to a more proinflammatory phenotype [192], as well as inhibit macrophage proliferation and increase cytotoxic T-cell tumour infiltration in HCC tumours in mice [193].